What is Epithalon?

What sources report

Papers spell it epitalon, epithalon or epithalone, and some use the one-letter code of its four amino acids, AEDG.¹¹⁴ It was developed by Vladimir Khavinson's research group in St. Petersburg, modeled on epithalamin, a mixture of peptides taken from cattle pineal glands.¹³ That group also ran most of the pharmacology studies, FDA notes, and a 2026 review finds little independent confirmation.²³

Epitalon is not epithalamin

FDA counts the synthetic peptide and the extract as separate substances, and the 2026 review warns that findings for the extract are not direct evidence for epitalon.²³ That matters because the best-known human results belong to the extract: 1.6 to 1.8-fold lower mortality over 6 to 8 years in the epithalamin group of a 266-person study of older adults, and 28% fewer deaths after 12 years among elderly heart patients.¹⁵¹⁶ Neither result transfers to epitalon.³

Telomeres in cell cultures

Khavinson's lab reported in 2003 that human fetal lung fibroblasts, which normally make no telomerase, began producing the enzyme and grew longer telomeres when epitalon was added to the culture.⁹² In a 2004 follow-up, untreated fibroblasts stopped dividing at passage 34, while treated cells made 10 extra divisions, to passage 44, and kept dividing.¹⁷ An independent lab at Brunel University London repeated the work in 2025. Normal human fibroblasts and breast epithelial cells gained telomere length through more telomerase, while two breast cancer cell lines gained it mainly through ALT (alternative lengthening of telomeres).¹⁸³ The journal later corrected three of the paper's figures, and the 2026 review urges caution with the telomerase results.¹⁹³ No human study identified by FDA or the review measured telomere length in the body.³²

Lifespan and tumors in animals

• Fruit flies (2000): flies raised on food containing epitalon, from egg to larva only, lived 11 to 16% longer as adults, and larger amounts did not add to the gain.¹¹
• Female CBA mice (2001): monthly injection courses from 6 months of age raised mean survival by 5.3%, with fewer spontaneous tumors, mainly lung adenomas.¹²²
• Female SHR mice (2003, 54 per group): average lifespan stayed the same. The last 10% of survivors lived 13.3% longer, leukemia was 6 times rarer, and overall tumor incidence did not change.²⁰
• HER-2/neu mice (2002), bred to develop breast tumors: fewer and smaller tumors, without a significant change in tumor incidence.²¹³ Vilon, a related Khavinson peptide, increased mammary cancer incidence in the same study.²¹

Melatonin, cortisol and blood sugar

• Old female rhesus monkeys (2001): after 10 days of injections into muscle, evening melatonin was more than 4 times higher and evening cortisol about 30% lower, while the melatonin of young monkeys did not change.²¹⁰
• Old rhesus monkeys (2005): basal glucose and insulin fell and night melatonin rose, while young monkeys did not change.²²
• Isolated rat pineal glands (2003): epitalon did not change melatonin release from young or old glands.²³
• Night-shift women aged 40 to 50 (2020): 40 women with low melatonin output were randomized to placebo or an under-the-tongue spray for 20 days. A urine melatonin metabolite rose 1.7-fold with epitalon, and two clock genes in white blood cells moved toward reference values; blinding was not specified.²⁴²³
• Elderly people with weak pineal function (2007, in Russian): night melatonin rose in the 15 people given epitalon.²⁵³

None of these studies measured sleep itself.² Other compounds researched for sleep are compared in Peptides and sleep.

Eyes, skin and other cell work

In a 2002 paper, epitalon injected near the eye preserved retinal structure and electrical activity in rats with inherited retinal degeneration. The same paper reported 162 patients with retinitis pigmentosa given injections next to the eyeball, with a positive clinical effect in 90%, but the 46 comparison patients received conventional therapy, not placebo.²⁶³ Skin evidence is limited to rat skin explants and rat skin cells.³ Cell studies also report less oxidative stress in damaged human retinal cells and more nerve-development gene activity in human gum stem cells.³¹⁴ These do not establish tissue repair in living animals or people, and no completed human study has measured skin outcomes.³ Related research is mapped in Peptides and skin and hair.

What the research does not cover

As of October 24, 2026, ClinicalTrials.gov listed no trial of epitalon alone.²⁷ No adequately powered randomized trial has tested sleep, telomeres in the body, lifespan or disease outcomes.³ Researchers who need the compound for lab work can find Epithalon for sale as a research vial.

Side effects

No side-effect profile exists for epitalon in people, because no clinical study has assessed its safety.² FDA found no reports in its adverse event database (FAERS) through December 8, 2025, but notes that reporting is voluntary and incomplete, so an empty search does not show safety.² Two small Russian studies said they saw no side effects or treatment complications without describing how they checked, and the night-shift spray study reported no safety data.²⁵³²

Warnings

• Cancer question: epitalon switches on telomerase, and longer telomeres are generally associated with higher cancer risk, so FDA says it has the potential to be carcinogenic from a mechanistic standpoint.² The mouse tumor studies used one fixed dose, female mice only and at most about 22 weeks of total exposure, so FDA says they do not adequately show whether epitalon could cause cancer.²
• Cancer cells: telomeres also lengthened in two breast cancer cell lines. The 2026 review says this does not show that epitalon causes cancer, but that it can act on telomere upkeep in cancer cells as well as normal ones, with unknown long-term consequences.¹⁸³
• Immune reactions: FDA says peptide aggregation and synthesis impurities may trigger immune responses, from symptomless antibodies to life-threatening reactions.²
• Untested areas: FDA found no acute, repeat-dose, reproductive or developmental toxicity studies, so effects in pregnancy and with long-term use are unknown.²
• Product quality: FDA judged both forms not well characterized, and the certificates it reviewed lacked results for tests that matter for injectables, such as endotoxins and aggregates.²
• Unauthorized products: Health Canada warns that unauthorized injectable peptides may lead to infections and allergic reactions and may contain unlisted ingredients or contaminants.²⁸²⁹

Dosage information

No human dose of epitalon is established.³ FDA identified no pharmacokinetic studies in people, and the 2026 review says dose-ranging data are inadequate and that the mix of species, routes, doses and schedules prevents a reliable estimate of an optimal human regimen.²³ The table records what researchers gave in published studies; it is not guidance for anyone, and animal amounts must not be converted into human doses.²³

Doses quoted online

FDA found clinic websites quoting daily doses in milligrams, by injection or by mouth, often in cycles.² No human study identified by FDA or the 2026 review used amounts like these: the one published study of epitalon injected into muscle in people used 0.01 mg a day, hundreds of times less.³ Injections of 10 mg belong to studies of epithalamin, a different product.³¹⁶

Reconstitution and storage

Epithalon is supplied as a white freeze-dried powder, 10 mg per vial, with no diluent included.⁵ As it is not an approved drug, there are no FDA-reviewed mixing or storage directions; the figures below come from the supplier and from vendor data cited by FDA.²

• Powder: the supplier gives 36 months at -20 °C or 30 days at 2 to 8 °C.⁵ Vendor data cited by FDA say the freeze-dried free base lasts 3 weeks at room temperature but should be kept dry below -18 °C, since moisture shortens the life of freeze-dried peptides.²
• In solution: the same data give 2 to 7 days at 4 °C for the free base, and below -18 °C for later use.²
• Acetate salt: up to 3 years at -20 °C as a powder and 1 year in solvent at -80 °C.²
• Solubility: how well epitalon dissolves in water is poorly documented, and FDA doubts that a free base solution as strong as 3 mg/mL can be made with water alone.²

Lab steps are in the reconstitution guide, concentration math in the reconstitution calculator, and storage basics in How to store peptides.

Regulatory status

United States. FDA has never approved epitalon. Its May 2026 review found that no approved drug contains it and that it has no USP or National Formulary monograph.² A US orphan drug designation for retinitis pigmentosa, granted September 2, 2010, was withdrawn or revoked on January 6, 2016.²

Compounding. Epitalon was once in category 2 of FDA's interim compounding policies until its nominators withdrew it, and FDA still notes a possible risk of immune reactions for certain routes.³⁰ FDA then reviewed it on its own initiative for insomnia, and its staff proposed keeping it off the 503A bulks list, citing poor characterization, no evidence of effectiveness, no clinical safety data and immunogenicity concerns.² The Pharmacy Compounding Advisory Committee took separate votes on the free base and the acetate on July 24, 2026. Healio reported 7 yes, 4 no and 1 abstention on epitalon, a recommendation to list it that went against FDA's reviewers.³¹³²³³ Committee advice is not binding, and a listing would not amount to a drug approval.³³ As of October 24, 2026, FDA had posted no minutes or decision, and the Federal Register showed no new 503A bulk substance documents since July 25, 2026.³⁴³⁵ Until that changes, epitalon meets none of the conditions section 503A sets for a compounding ingredient.³⁶²⁶

Enforcement. FDA's 2020 warning letter to a Kentucky compounding pharmacy listed Epitalon among ineligible substances it had compounded.³⁶ In an August 2026 letter to an online peptide seller, which did not name epitalon, FDA wrote that "research use only" labels did not change the fact that the seller's website showed its products were drugs for human use.³⁷

Elsewhere. FDA found no approved epitalon product in the ten countries it checked, including Canada, Australia and the United Kingdom, and none authorized by the European Medicines Agency.² In Canada, injectable peptides are prescription drugs; Health Canada named Epitalon among unauthorized injectable peptides it seized in 2025 and 2026, and says a research-use label does not make such a product legal.²⁸²⁹ Belgian public health scientists identified epitalon in two illegal pharmaceutical preparations in 2015.³⁸

Sport. USADA says the 2027 WADA Prohibited List, in effect from January 1, 2027, names peptides in general in class S0, banned at all times; its advisory does not name epitalon.⁷